Background Numerous clinical trials have supported psychedelic-assisted therapy (PAT) as a treatment for psychiatric disorders such as depression, anxiety, post-traumatic stress, and substance use. While empirical evidence indicates PAT’s benefits, the perspectives of mental health practitioners on this topic remain unclear.Methods This quantitative study attempted to capture psychoanalyst...
AbstractPurpose of ReviewOn 1 July 2023, the Therapeutic Goods Administration approved 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for the treatment of post‐traumatic stress disorder (PTSD). Accordingly, the purpose of this review is to provide an overview of MDMA and what pharmacists should know as this treatment emerges.Sources of InformationEMBASE, MEDLINE, and CINAHL...
This essay discusses the potential clinical use of 3,4methylenedioxymethamphetamine (MDMA) with patients diagnosed with Post Traumatic Stress Disorder (PTSD). We present a brief history of the use of consciousness-altering substances from ancient times to the present as well as recent research on psychedelic assisted psychotherapy (PAP). Double blind investigation in which some of the...
Recent research into psychedelics has found them to be an effective treatment for disorders related to depression, anxiety, and post traumatic stress disorder. Mystical experiences have proven to mediate the therapeutic effects for outcomes; however, Spanish measures have not been studied thoroughly. In this study we explored the psychometric properties of the Mystical Experience Questionnaire...
Psychedelic MedicineJune 1, 2024Abshir S Adam, Kayleigh S. Lamalfa, Yasaman Razavi et al.6 citations
Frontline antidepressants such as selective serotonin reuptake inhibitors (SSRIs) leave many patients with unmet treatment needs. Moreover, even when SSRIs reduce depressive symptoms, anhedonia, the loss of pleasure to previously rewarding activities, often remains unabated. This state of affairs is disheartening and calls for the development of medications to more directly treat anhedonia. The...
Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTSD) with a prevalence of up to 10% in bereaved populations. Hallmarks of PGD include functional impairment a year or more post-bereavement and intense yearning for the deceased. Current treatments for PGD are typically psychological rather than...
Fear-related disorders, including post-traumatic stress disorder (PTSD), and anxiety disorders are pervasive psychiatric conditions marked by persistent fear, stemming from its dysregulated acquisition and extinction. The primary treatment for these disorders, exposure therapy (ET), relies heavily on fear extinction (FE) principles. Adolescence, a vulnerable period for developing psychiatric...
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various disorders, such as major depressive disorder (MDD). However, the non-medical use of these substances became rampant due to their hallucinogenic effects, leading to their classification as narcotics in numerous countries by the 1970s. Since the 1990s,...
MDMA-assisted psychotherapy has emerged as a potential treatment for psychiatric illnesses, with findings from clinical trials in the last decade demonstrating safety and efficacy in the treatment of posttraumatic stress disorder (PTSD), among other psychiatric indications. Earlier this year (2024), the Food and Drug Administration in the United States granted priority review for a new drug...
Hallucinogenics are a broad category of psychoactive substances that have the ability to alter the senses of smell, taste, hearing and feeling, as well as mood and thought. They fall under three main categories: psychedelics, dissociatives and deliriants. Muscle spasms, aggressive behaviour, convulsions, and in some cases unconsciousness, are among the dangers associated with their use....